相关临床试验
7
1 进行中
药物批准
7
批准总数
监管机构
2
监管机构数
成立时间
N/A
进行中（未招募）
1
14.3%
已完成
6
85.7%
- Biocon Pharma Limited has received U.S. FDA approval for its generic everolimus tablets for oral suspension in 2 mg, 3 mg, and 5 mg strengths. - The medication is indicated for treating adult and pediatric patients aged 1 year and older with Tuberous Sclerosis Complex who have Subependymal Giant Cell Astrocytoma. - The approval also covers adjunctive treatment of TSC-associated partial-onset seizures in patients aged 2 years and older. - This FDA approval strengthens Biocon's portfolio of vertically integrated drug products and addresses significant unmet medical needs.
- Samsung Bioepis is exploring the acquisition of its U.S. sales partner Organon as part of a strategic shift from indirect to direct sales to capture higher profit margins and strengthen market control. - The company has already begun transitioning to direct sales in Europe, reclaiming commercialization rights for Byooviz from Biogen and now directly selling four products in the European market. - This strategic pivot comes as Samsung Bioepis faces intensifying biosimilar competition and seeks to maximize cash generation to fund its new drug development pipeline, including ADC candidates developed with partners like IntoCell. - The move aligns with broader industry trends as drug price-cut policies create opportunities for biosimilar companies while increasing competitive pressure in the global market.
- Biocon Ltd is considering merging its biosimilars subsidiary Biocon Biologics Ltd, valued at approximately $4.5 billion, with the parent company as an alternative to a standalone IPO. - The company has appointed Morgan Stanley to evaluate strategic options including merger, IPO, or share swap structures to unlock shareholder value more effectively. - Biocon Biologics' $3.3 billion acquisition of Viatris' global biosimilars business in 2022 created $1.2 billion in debt, pressuring IPO valuations and prompting the strategic review. - The board committee continues evaluating restructuring options while market volatility and acquisition debt influence the decision between merger and public listing pathways.
- Alvotech announced significant leadership changes with Chief Commercial Officer Anil Okay stepping down to become CEO of Adalvo, marking a strategic transition in the company's commercial operations. - The biosimilar company appointed three experienced pharmaceutical executives to key positions: Trisha Durant as Senior VP of Global Business Development, Harshika Sarbajna as Senior VP Commercial North America, and Agne Pasko as VP Head of Business Development. - The leadership restructuring comes as Alvotech continues expanding its global commercial partnerships for biosimilar medicines, with two products already approved and nine candidates in development targeting autoimmune disorders, cancer, and other therapeutic areas.
- Sandoz reached a settlement agreement with Regeneron allowing launch of ENZEEVU (aflibercept-abzv) biosimilar in the fourth quarter of 2026. - Formycon settled its BPCIA litigation with Regeneron, resulting in dismissal of all claims and vacation of the preliminary injunction against AHZANTIVE (aflibercept-mrbb). - The settlements are part of ongoing multi-district litigation involving multiple biosimilar developers challenging Regeneron's aflibercept patents for neovascular age-related macular degeneration treatment.
- Biocon Pharma Limited has received U.S. FDA approval for tofacitinib extended-release tablets, expanding access to this JAK inhibitor therapy. - The approval represents a significant regulatory milestone for Biocon's pharmaceutical division in the competitive immunology market. - Tofacitinib extended-release formulation offers potential dosing convenience advantages over immediate-release versions for patients with autoimmune conditions.
- President Trump announced 100% tariffs on all imported branded and patent-protected medicines to the US starting October 1, 2025, unless companies are actively building manufacturing plants in America. - Indian pharmaceutical stocks plummeted up to 5% following the announcement, with Sun Pharma hitting its yearly low and the Nifty Pharma Index declining 2.54%. - The policy could significantly impact Indian pharma companies that generate substantial revenue from US exports, potentially affecting over $233 billion of US pharma imports while exempting generic drug exporters. - Companies may face reduced profits or be forced to invest in expensive US manufacturing facilities to avoid the tariffs and maintain market access.
- Biocon Biologics secured FDA approval for denosumab biosimilars Prolia and Xgeva, representing a $4.5 billion US market and $7 billion global opportunity. - The company achieved four FDA approvals in 10 months, expanding its US portfolio to nine products with early-mover advantage in the denosumab market. - New USFDA draft guidelines eliminating phase-III trial requirements for certain biosimilars could significantly reduce Biocon's R&D costs and accelerate future launches. - Biocon's cancer therapies Fulphila and Ogivri already hold over 25% market share in the US, demonstrating the company's competitive positioning in biosimilars.
- The Federal Court of Australia denied Regeneron and Bayer's preliminary injunction application against Sandoz's aflibercept biosimilars, allowing the launch of Afqlir and Enzeevu to proceed as planned. - Justice Rofe found insufficient likelihood of patent infringement success, ruling that dosing regimens measured in "weeks" versus "months" are not equivalent under patent claim construction principles. - The decision continues Australia's trend of refusing preliminary injunctions in pharmaceutical patent cases since 2018, with the court rejecting arguments about international price referencing effects as "speculative." - Sandoz's biosimilar launch will trigger a 25% PBS price reduction for Eylea 2mg, but the court noted Regeneron was already cannibalizing its own market through transition to Eylea 8mg.
- Sandoz secured a patent settlement with Regeneron in September 2025, clearing legal hurdles for its FDA-approved aflibercept biosimilar Enzeevu™ to launch by end of 2026. - The resolution positions Sandoz advantageously in the competitive $4.767 billion U.S. aflibercept market, where multiple biosimilars are vying for share against Regeneron's Eylea. - Enzeevu's interchangeable designation allows automatic pharmacy substitution, potentially enabling premium pricing compared to competitors like Amgen's Pavblu which launched with 10% discount. - The settlement demonstrates strategic value of early patent dispute resolution in the rapidly growing biosimilar market projected to reach $3.2 billion by 2033.
